Indiana Medicaid does not cover Zepbound for weight loss. The only route to coverage is a narrow exception for adults who have obesity together with moderate to severe obstructive sleep apnea, and even then the prescription has to clear a detailed prior authorization.
Why Weight Loss Alone Won’t Qualify
Indiana’s Medicaid pharmacy benefit page states plainly that “medications used for weight loss” are not covered.1Indiana Medicaid. Pharmacy Benefits The exclusion runs across Hoosier Healthwise, the Healthy Indiana Plan, and the managed care plans. It reflects a longstanding federal provision letting states opt out of covering anti-obesity drugs under the Medicaid Drug Rebate Program, and Indiana has opted out.2KFF. Medicaid Coverage of and Spending on GLP-1s
Zepbound and Wegovy are both flagged in Indiana Medicaid’s prior authorization criteria as “not covered exclusively for weight loss.”3Optum Rx Indiana Medicaid. GLP-1 RA/GIP Combinations Prior Authorization Criteria The word “exclusively” is what opens the door. Zepbound can be authorized, but the prescription has to be tied to a covered medical condition beyond weight itself.
The Sleep Apnea Exception
Since April 2025, Indiana Medicaid has authorized Zepbound for adults with moderate to severe obstructive sleep apnea (OSA) who also have obesity. The FDA approved Zepbound for this indication in December 2024, and because Medicaid programs are generally required to cover drugs for their medically accepted indications, Indiana built a prior authorization pathway for it.3Optum Rx Indiana Medicaid. GLP-1 RA/GIP Combinations Prior Authorization Criteria
To be approved, a patient must meet all of the following:
- Be 18 or older.
- Have moderate to severe OSA with obesity, confirmed by a sleep study showing an apnea-hypopnea index (AHI) of 15 or more events per hour, or a documented AHI at that level plus current use of a CPAP or BiPAP machine.
- Have a BMI of 30 kg/m² or higher, documented within the past three months.
- Not have Type 1 or Type 2 diabetes, with an HbA1c below 6.5%.
- Have a prescriber attestation that the medication will be used alongside a reduced-calorie diet and increased physical activity.
- Be prescribed no more than 15 mg per week.
- Not be taking another GLP-1 receptor agonist or tirzepatide product at the same time.
How often does this actually approve? The state’s PDL program evaluation for July 2024 through June 2025 reported a combined 24 prior authorizations approved for Wegovy and Zepbound during the period.4Indiana General Assembly. Evaluation of the Indiana Medicaid Preferred Drug List Program, FY 2025 The pathway exists, but very few people are getting through it.
Renewing the Authorization After Year One
Initial approval lasts one year. To keep it, three things have to be true at renewal: the patient took the medication consistently (at least 84 days out of the prior 112), they lost at least 5% of baseline body weight, and their AHI improved or they are still using CPAP or BiPAP.3Optum Rx Indiana Medicaid. GLP-1 RA/GIP Combinations Prior Authorization Criteria
If You Have Type 2 Diabetes
Zepbound is walled off from anyone with a diabetes diagnosis. If a patient has Type 2 diabetes and needs tirzepatide, Indiana Medicaid covers Mounjaro instead, which is the same drug under its diabetes label. Mounjaro requires the patient to have tried and failed two preferred GLP-1 medications first.5Optum Rx Indiana Medicaid. GLP-1 RA/GIP Combinations Prior Authorization Criteria
Children and Teens Are Not Covered
Federal Medicaid law requires states to cover medically necessary treatments for members under 21 through the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) program, even where the state otherwise excludes a drug class. Indiana uses EPSDT to cover certain weight-loss medications for minors, but only Wegovy and Saxenda, per a 2023 IHCP bulletin.6Indiana Medicaid. IHCP Bulletin BT2023148 Zepbound is not on that list, and its prior authorization criteria require members to be at least 18.3Optum Rx Indiana Medicaid. GLP-1 RA/GIP Combinations Prior Authorization Criteria Zepbound is FDA-approved only for adults; an adolescent tirzepatide trial is not expected to produce results until 2027.7FDA. Zepbound NDA Approval Letter
How Managed Care Plans Handle It
Most Indiana Medicaid members are enrolled in a managed care plan, and those plans must follow the state’s uniform preferred drug list. The wording in each plan’s formulary is different, but the coverage rules are the same.
CareSource lists Zepbound on its preferred drug list as a Tier 2 medication requiring prior authorization, and its coverage terms track the statewide criteria: OSA only, no diabetes.8CareSource. Indiana Medicaid Preferred Drug List9CareSource. Pharmacy Policies – Medicaid Managed Health Services is blunter. Its formulary excludes “drugs prescribed for weight loss (with the exception of Orlistat)” and does not list Zepbound at all.10Managed Health Services Indiana. MHS Indiana Medicaid Formulary
As of July 2025, Zepbound moved to preferred status on the statewide uniform preferred drug list, up from neutral.11Indiana Medicaid. IHCP Bulletin BT202572 That change affects how pharmacy benefits are processed. It does not change what the drug can be prescribed for.
What to Do If You Don’t Qualify
Eli Lilly’s manufacturer savings card and self-pay program exclude anyone enrolled in Medicaid or other government-funded insurance, and Lilly Cares, the company’s patient assistance program, does not currently include Zepbound.12Eli Lilly. Coverage and Savings13FindHonestCare. Zepbound Patient Assistance
Cash-pay is available regardless of insurance status. Through Lilly’s LillyDirect platform, the Zepbound single-dose vial runs $299 per month for the lowest dose, scaling up to $449 per month at maintenance doses.12Eli Lilly. Coverage and Savings These are still meaningful monthly costs on a Medicaid budget.
If you think you meet the OSA criteria, ask your prescriber to submit a prior authorization with the full documentation package: a recent sleep study showing your AHI, BMI records within the last three months, and current HbA1c results. Eli Lilly’s provider support line (1-800-545-5979) offers help with benefits verification and sample letters of medical necessity for appeals.12Eli Lilly. Coverage and Savings